<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>i2O Therapeutics — Prospect Detail</title>
  <link rel="stylesheet" href="styles.css">
</head>
<body>
<header class="site-header"><h1>Prospect Detail</h1></header>
<div class="container">
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
  <div class="detail-header">
    <span class="badge health" style="font-size:.8rem;">Biotech / Drug Delivery</span>
    <h1>140. i2O Therapeutics</h1>
    <p class="meta">Oral Insulin Using Ionic Liquid Technology</p>
  </div>
  <div class="section"><h3>1. Startup Name</h3><p><strong>i2O Therapeutics</strong></p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Tell me more about this company's origin story...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>2. Founder Contact</h3><p><strong>Samir Mitragotri</strong></p><p>Wyss Institute / Harvard SEAS</p><p>Dr. Mitragotri is a leading expert in drug delivery and biomaterials; Wyss Core Faculty member</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Research the founder's background and credentials...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>3. Product Overview</h3><p>i2O Therapeutics develops oral formulations of insulin and other injectable biologics using proprietary ionic liquid technology. The platform enables proteins like insulin to survive the harsh gastrointestinal environment and be absorbed into the bloodstream, potentially replacing daily injections with oral pills. For the 450+ million diabetics worldwide who require insulin injections, an oral alternative would be transformative for quality of life and adherence.</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="What competitors does this product face?">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>4. Funding Stage</h3><p><strong>Seed — $4M</strong> — Funded by Sanofi and JDRF to advance oral insulin development.</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="What's the typical next funding milestone?">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>5. How I Found the Company</h3><p>Discovered through Wyss Institute portfolio and diabetes innovation research.</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Find more recent news about this company...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="strengths-weaknesses">
    <div class="section"><h3>Strengths</h3><ul><li><strong>Holy grail opportunity:</strong> Oral insulin has been sought for decades; massive patient demand.</li><li><strong>Strategic backers:</strong> Sanofi (major insulin maker) and JDRF validation.</li><li><strong>Expert founder:</strong> Dr. Mitragotri is a world leader in drug delivery science.</li></ul>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Validate these strengths with market data...">
        <button>Ask AI</button>
      </div>
    </div>
    </div>
    <div class="section"><h3>Weaknesses</h3><ul><li><strong>Many have failed:</strong> Oral insulin attempts have a long history of clinical failures.</li><li><strong>Early stage:</strong> Seed funding with significant development milestones ahead.</li><li><strong>Bioavailability challenges:</strong> Achieving sufficient insulin absorption orally is technically difficult.</li></ul>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="What other risks should I consider?">
        <button>Ask AI</button>
      </div>
    </div>
    </div>
  </div>
  <div class="section"><h3>7. Five Questions for the Team</h3><ol class="questions-list"><li>What oral bioavailability have you achieved in preclinical studies?</li><li>How does your ionic liquid approach differ from previous oral insulin attempts?</li><li>What is your timeline to clinical trials?</li><li>What is Sanofi's ongoing involvement beyond the initial investment?</li><li>Are you pursuing other injectable biologics beyond insulin with this platform?</li></ol>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Generate additional due diligence questions...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section email-draft">
    <h3>8. Draft Outreach Email</h3>
    <div class="email-box">
      <p><strong>Subject:</strong> Harvard Undergraduate Capital Partners — Oral Insulin Innovation</p>
      <p>Dear Dr. Mitragotri,</p>
      <p>I'm reaching out from <strong>Harvard Undergraduate Capital Partners (HUCP)</strong>, a student-run investment group at Harvard focused on early-stage ventures led by Harvard-affiliated founders.</p>
      <p>We've been following i2O Therapeutics's work on oral insulin with great interest. The potential to replace daily injections with an oral pill for the 450+ million diabetics worldwide would be genuinely transformative. Your ionic liquid platform, developed at the Wyss Institute, represents a novel approach to a challenge that has eluded the pharmaceutical industry for decades. The backing from Sanofi and JDRF speaks to the credibility of the science.</p>
      <p>Would you be open to a brief conversation about i2O's journey and the path ahead? We'd love to learn from your experience and explore how HUCP might support this important work.</p>
      <p>Thank you for your time.</p>
      <p>Best,<br>[Your Name]<br>Harvard Undergraduate Capital Partners</p>
    </div>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Personalize this email with more specific details...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
</div>
<script src="script.js?v=4"></script>
</body>
</html>
